EARN25

Eli Lilly Stock Stumbles on FDA Rejection

Options Bears are targeting LLY at double the intraday average

Deputy Editor
Jan 20, 2023 at 11:15 AM
facebook X logo linkedin


The U.S. Food and Drug Administration (FDA) rejected the accelerated approval of Eli Lilly and Co's (NYSE:LLY) experimental Alzheimer's drug due to a lack of enough trial data from patients treated for at least a year. Jefferies called this setback a "modest positive" for rival Biogen (BIIB). 

At last glance, Eli Lilly stock was down 1.2% at $347.01, earlier as low as $344.58. The stocks 100-day moving average kept losses in check, however. Year-over-year, LLY is outperforming with a 42.7% year-over-year lead. 

The majority of analysts are bullish on LLY, with 14 of the 16 in coverage carrying a "buy" or better rating. Plus, the 12-month consensus price target of $389.52 is a 12.3% premium to current levels. 

Options bears are targeting LLY after today's news. So far, 3,121 puts have been exchanged, which is double what's seen at this point. The weekly 3/3 320-strike put is the most popular, where new positions are being sold to open. 

 

You Don’t Need 25 Alerts -- You Need ONE You Can Trust!

That’s the idea behind Trade of the Week, Schaeffer’s newest trade alert.

Every Monday morning before the opening bell, you’ll receive a single, expertly researched trade recommendation -- built from the same proprietary research we’ve been using for over four decades.

It’s not just a signal.

It’s a plan designed for traders who are tired of jumping from alert to alert without ever finding their edge.

No juggling alerts. No switching directions mid-week. Just one clear, expertly researched trade idea -- delivered before the market even opens.

👉 JOIN RIGHT NOW FOR JUST $1 TO GET THE NEXT TRADE!